RuiZhou Bio Announces Tens of Millions RMB Series A+ Financing Led by Changxing Fund, WinX Capital as Exclusive Financial Advisor
Reinovax Biologics
Biological Products Research and Development, Manufacturer
WinX Capital
Investment Institutions in the Greater Health Field
VCBeat has learned that recently,Shanghai Reinovax Biologics Co., Ltd. (hereinafter referred to as “Reinovax Biologics”) announced the completion of its tens-of-millions-yuan Series A+ financing round. This round was led by Changxing Fund, with WinX Capital serving as the exclusive financial advisor.Previously, the company received a total of RMB 290 million in funding support from Changchun High-Tech Industry (Group) Co., Ltd. and its controlled subsidiary, Bacchus Biology. The funds raised in this round of financing will be primarily used for the clinical development and commercial launch of the company’s core product, the 24-valent pneumococcal polysaccharide conjugate vaccine, for indications in adults and infants.
Reinovax Biologics was founded in September 2017 by Dr. Zhu Xianchao, a senior expert who returned to China from abroad. Its core product is the “24-valent Pneumococcal Polysaccharide Conjugate Vaccine,” a first-in-class novel drug featuring a globally pioneering, non-toxic dual-protein carrier platform developed entirely in-house. Designed based on the epidemiological characteristics of pathogenic Streptococcus pneumoniae serotypes in China, this vaccine offers superior efficacy compared to currently marketed pneumococcal polysaccharide vaccines, increasing protection coverage from the current 75% to over 90% and effectively addressing the growing challenge of antibiotic resistance. The company has obtained clinical trial approval for indications across all age groups; clinical Phase II trials for the adult indication have been completed, with Phase III trials imminent, while preliminary Phase I data have been obtained for the infant and young child indication.
To achieve a comprehensive layout across the entire industry chain, in March 2021, Reinovax Biologics invested over RMB 120 million to establish Shanghai Weizhou Biotechnology Co., Ltd. in Lingang, Shanghai. The company built a high-standard GMP-compliant pilot-scale R&D and production facility with a total area of 5,026 square meters, which can significantly accelerate the pilot-scale R&D of innovative projects, the preparation of clinical samples, and IND filings.
About Reinovax Biologics
Reinovax Biologics is a developer and manufacturer of biologics, dedicated to advancing the discovery, preclinical research, pilot-scale process scale-up, and clinical studies of novel vaccines, antibodies, and recombinant protein therapeutics. In 2024, Reinovax Biologics was recognized as a National High-Tech Enterprise and a Shanghai Innovative Small and Medium-sized Enterprise. The company’s founder, Dr. Zhu Xianchao, previously served as Chief Scientific Officer at several renowned pharmaceutical companies. He specializes in research on recombinant proteins and novel vaccines, is a member of the International Society for Vaccines and the American Protein Society, and possesses extensive experience in vaccine development, medical translation, and industrialization.
About WinX Capital
WinX Capital is a leading investment bank in China’s healthcare industry, headquartered in Beijing and Shanghai, with offices in Shenzhen and Hangzhou. It has received numerous accolades, including Qimingpian’s “No. 1 Financial Advisor in Healthcare for 2024,” Diyi Xinsheng’s “No. 1 Financial Advisory Firm in Healthcare from 2022 to 2024,” and VCBeat’s “Annual Healthcare Financial Advisor among the Future Healthcare 100 (2022–2024).”